Continuous use of SGLT2 inhibitor versus DPP4 inhibitor initiation was associated with a lower risk of AD (HR [95% CI]: 0.54 [0.41–0.71]) and VD (HR [95% CI]: 0.64 [0.48–0.85]). The gene discussed is DPP4; the disease is Alzheimer disease.